title: Anti-tumor activity of phenoxodiol: from bench to clinic.
abstract: A major limitation in the treatment of cancers is the prevalence of chemoresistant tumors. Chemotherapy agents induce cell death by activating apoptosis. However, most cancer cells express high levels of antiapoptotic proteins and, hence, are chemoresistant. Phenoxodiol, a novel isoflavone derivative, has been shown to induce apoptosis both in vitro and in vivo, even in chemoresistant cancer cells. In addition, phenoxodiol has been shown to chemosensitize resistant cancer cells to commonly used chemotherapy agents, such as carboplatin and paclitaxel. This review will discuss the characterization of phenoxodiol's molecular mechanism and its current state in the clinic.
authors.affiliation: Yale University, Department of Obstetrics and Gynecology and Reproductive Sciences, School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA.
authors.forename: Ayesha B
authors.initials: AB
authors.lastname: Alvero
authors.forename: Michael
authors.initials: M
authors.lastname: Kelly
authors.forename: Patti
authors.initials: P
authors.lastname: Rossi
authors.forename: Aliza
authors.initials: A
authors.lastname: Leiser
authors.forename: David
authors.initials: D
authors.lastname: Brown
authors.forename: Thomas
authors.initials: T
authors.lastname: Rutherford
authors.forename: Gil
authors.initials: G
authors.lastname: Mor
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor / Q000187:drug effects; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology / Q000627:therapeutic use*; D008246:Lysophospholipids / Q000378:metabolism; D008297:Male; D008954:Models, Biological; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D013110:Sphingosine / Q000031:analogs & derivatives / Q000378:metabolism; D059005:Topoisomerase II Inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D007529:Isoflavones; D008246:Lysophospholipids; D009363:Neoplasm Proteins; D059005:Topoisomerase II Inhibitors; C060506:sphingosine 1-phosphate; C471183:phenoxodiol; D013110:Sphingosine